Bruker Corporation (NASDAQ:BRKR) Q2 2023 Earnings Conference Call August 3, 2023 8:30 AM ET Company Participants Justin Ward - Senior Director of IR & Corporate Development Frank H. Laukien - Chairman, President & CEO Gerald N. Herman - EVP & CFO Conference Call Participants Puneet Souda - Leerink Partners Michael Ryskin - Bank of America Joshua Waldman - Cleveland Research Daniel Arias - Stifel, Nicolaus & Company Patrick Donnelly - Citigroup Daniel Brennan - TD Cowen Rachel Vatnsdal - J.P. Morgan Jack Mee ...

会议主要讨论的核心内容 - 公司正在通过Project Accelerate 2.0和运营卓越计划实现更高的有机增长和利润率 [7][8][11] - 公司在蛋白质组学和空间生物学领域进行大量投资,预计未来这些将成为公司50%的收入 [44][45] - 公司的MALDI BioTyper产品在临床蛋白质组学应用中占据主导地位 [30][31][32][33][34] - 公司在清洁能源、半导体测量等领域也有重要布局和进展 [35][36][37][39] - 公司的timsTOF质谱平台在蛋白质组学领域持续创新,为客户带来速度、灵敏度和特异性的提升 [51][52][53][54][55][56][57][58][59][60][61][62][63][64][65][66][67][68][69][70][71][72][73] - 公司收购的Biognosys公司在蛋白质组学服务和软件方面为公司带来了协同效应 [74][75][76][77][78][79][80][81][82][83][84][85][86] 问答环节重要的提问和回答 无相关内容

财务表现 - 2023年第一季度，Bruker公司的产品收入为5.67亿美元，较去年同期增长了15.4%[5] - 2023年第一季度，Bruker公司的总营收为6.85亿美元，较去年同期增长了15.3%[5] - 2023年第一季度，Bruker公司的净利润为7,740万美元，较去年同期增长了24.6%[5] - 2023年第一季度，Bruker公司的每股净收益为0.52美元，与去年同期持平[5] - 2023年第一季度，Bruker公司的现金流量从经营活动中提供了8750万美元[8] 公司业务 - Bruker公司主要从事高性能科学仪器和分析解决方案的开发、制造和分销，涵盖生命科学研究、制药、生物技术、细胞生物学等领域[9] - Bruker公司设有四个报告部门，分别是Bruker Scientific Instruments (BSI) BioSpin、BSI CALID、BSI Nano和Bruker Energy & Supercon Technologies (BEST)[9] 各部门业绩 - BSI BioSpin部门2023年第一季度营收为180.3百万美元，较2022年同期增长13.8%[14] - BSI CALID部门2023年第一季度营收为236.7百万美元，较2022年同期增长16.5%[14] - BSI Nano部门2023年第一季度营收为209.6百万美元，较2022年同期增长17.4%[14] - BEST部门2023年第一季度营收为62.2百万美元，较2022年同期增长4.2%[14] 市场表现 - 美国市场2023年第一季度营收为175.1百万美元，较2022年同期增长13.0%[14] - 德国市场2023年第一季度营收为62.6百万美元，较2022年同期增长6.8%[14] - 中国市场2023年第一季度营收为107.6百万美元，较2022年同期增长24.7%[14] 公司收购情况 - 公司2023年1月收购Biognosys，AG，购买价格为7500万瑞士法郎（约合8010万美元），并将其整合到BSI CALID部门[17] - 公司在2023年3月31日完成了多项收购，包括Biognosys，Acquifer Imaging GmbH和Deltabyte GmbH等[18] - 公司在2023年3月31日完成了对OSTHUS Beteiligungs GmbH的收购，获得了其60%的股权[19] 财务状况 - 公司剩余履约义务截至2023年3月31日约为23.83亿美元[15] - 截至2023年3月31日，公司合同资产为6.71百万美元，合同负债为5.10亿美元[16] - 公司的商誉在2023年3月31日达到了527.3百万美元，较2022年底增加了65.0百万美元[22] - 公司持有的无形资产包括现有技术、客户关系、商标等，总额为610.5百万美元[23] - 公司在2023年3月31日的债务总额为1,229.1百万美元，其中包括EUR notes、CHF notes和其他贷款[24]

Bruker Corporation (NASDAQ:BRKR) Q1 2023 Earnings Conference Call May 4, 2023 8:30 AM ET Company Participants Justin Ward - Senior Director of IR & Corporate Development Frank Laukien - Chairman, President & CEO Gerald Herman - EVP & CFO Conference Call Participants John Sourbeer - UBS Puneet Souda - SVB Securities Josh Waldman - Cleveland Research Daniel Arias - Stifel Patrick Donnelly - Citi Rachel Vatnsdal - JPMorgan Jack Meehan - Nephron Daniel Brennan - Cowen Brandon Couillard - Jefferies Matt Sykes - ...

Bruker Corporation (NASDAQ:BRKR) Cowen 43rd Annual Health Care Conference March 6, 2023 2:10 PM ET Company Participants Gerald Herman - EVP & CFO Conference Call Participants Max Masucci - Cowen & Co. Max Masucci Well again, welcome to TD Cowen's 43rd Annual Health Care Conference. I'm Max Masucci, one of the Life Science and Diagnostic Tools analysts here. We are pleased to be joined today by Bruker, one of the three large cap names in our coverage. And a diversified participant in several of the tools, di ...

Bruker Corporation (NASDAQ:BRKR) 2023 Citi Healthcare Services, Medtech, Tools & HCIT Conference March 2, 2023 9:30 AM ET Company Participants Gerald Herman - EVP & CFO Conference Call Participants Patrick Donnelly - Citi Patrick Donnelly All right. We can look to get started. Thanks, everyone for being here. I'm Patrick Donnelly, the Tools and Diagnostics analyst here at Citi. Happy to have Gerald Herman, CFO of Bruker with us for this session. Gerald Herman Hello. Patrick Donnelly Gerald, thanks for bei ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT of 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to __________ Commission File Number 000-30833 BRUKER CORPORATION (Exact name of registrant as specified in its charter) Delaware 04-3110160 (State or other jurisdi ...

Bruker Corporation (NASDAQ:BRKR) Q4 2022 Earnings Conference Call February 9, 2023 8:30 AM ET Company Participants Justin Ward - Senior Director of Investor Relations & Corporate Development Frank Laukien - Chairman, President and Chief Executive Officer Gerald Herman - Executive Vice President and Chief Financial Officer Conference Call Participants Puneet Souda - SVB Securities Patrick Donnelly - Citi Jack Meehan - Nephron Josh Waldman - Cleveland Research Rachel Vatnsdal - JPMorgan Derik Bruin - Bank of ...

Bruker Corporation (NASDAQ:BRKR) Q3 2022 Earnings Conference Call November 3, 2022 8:30 AM ET Company Participants Justin Ward - Senior Director of Investor Relations & Corporate Development Frank Laukien - Chairman, President & Chief Executive Officer Gerald Herman - Executive Vice President & Chief Financial Officer Conference Call Participants Jack Meehan - Nephron Patrick Donnelly - Citi Puneet Souda - SVB Securities Dan Arias - Stifel Josh Waldman - Cleveland Research Nisarg Shah - Bank of America Rach ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT of 1934 For the quarterly period ended September 30, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT of 1934 For the transition period from to Commission File Number 000-30833 BRUKER CORPORATION (Exact name of registrant as specified in its charter) Delaware 04-3110160 (State or other jurisdiction of incorp ...